Article | Open

Transition metal catalysis in the mitochondria of living cells

  • Nature Communications 7, Article number: 12538 (2016)
  • doi:10.1038/ncomms12538
  • Download Citation
Published online:


The development of transition metal catalysts capable of promoting non-natural transformations within living cells can open significant new avenues in chemical and cell biology. Unfortunately, the complexity of the cell makes it extremely difficult to translate standard organometallic chemistry to living environments. Therefore, progress in this field has been very slow, and many challenges, including the possibility of localizing active metal catalysts into specific subcellular sites or organelles, remain to be addressed. Herein, we report a designed ruthenium complex that accumulates preferentially inside the mitochondria of mammalian cells, while keeping its ability to react with exogenous substrates in a bioorthogonal way. Importantly, we show that the subcellular catalytic activity can be used for the confined release of fluorophores, and even allows selective functional alterations in the mitochondria by the localized transformation of inert precursors into uncouplers of the membrane potential.


The functioning of the cell depends on the regulated action of thousands of different enzymes that have evolved to catalyse a wide range of chemical reactions. In many cases, the correct working of these enzymes requires an appropriate localization in specific organelles and/or subcellular sites1. This is the case, for instance, for mitochondrial enzymes, which need to be associated with different mitochondrial components in order to exert their critical role in cellular respiration2,3,4.

Given the biological relevance of this type of intracellular localization, it is reasonable to envision that installing artificial enzymes with non-natural functions in designed cellular compartments might unveil new opportunities for probing and manipulating cell biology. While recent years have witnessed notable advances in the implementation of evolved enzymes capable of achieving in vitro non-natural transformations5,6,7, including artificial metalloenzymes8,9,10,11,12, engineering of this type of systems in in vivo settings is far from obvious.

An alternative and highly appealing way to generate localized, abiotic catalytic activities inside cells could be based on the targeted subcellular delivery of transition metal catalysts. However, achieving catalytic organometallic reactions inside living cells is not trivial, and many problems associated to the activity, stability, aqueous and biological compatibility, orthogonality, and cell entrance can be envisioned. The living cell is a very complex, compartmentalized and dynamic entity, with a very high concentration of biomolecules, ions and other structures in complex equilibrium, and can therefore be considered as a very stringent reaction medium.

Despite all these potential complications, recent data suggest that certain transition metal derivatives can promote intracellular reactions through typical organometallic mechanisms. Particularly relevant in this context has been the pioneering work by Meggers and coworkers, who demonstrated that discrete organoruthenium complexes could be used for the in cellulo uncaging of allylcarbamate protected (alloc) amines13,14. Our laboratory has reported that this type of catalysts can be employed for the uncaging of DNA binders15. Importantly, while these results point to intracellular reactions, a recent publication by Waymouth and Wender suggests that, at least in 4T1 cells, these Ru complexes are readily washed out with PBS, and raises doubts on the intracellularity of the metal catalysis16.

Other important contributions in the area of in cellulo metal catalysis deal with the use of palladium complexes, albeit success in these transformations seems to require the use of heterogeneous nanostructured palladium species, and in most of the cases, in cellulo imaging of the catalytic responses has been analysed after fixation of the cells17,18,19.

All these data confirm that achieving organometallic catalytic reactions of exogenous substrates within living cells is certainly tricky20,21,22,23,24,25. While the field is in its infancy and further progress requires the development of new biocompatible transformations, there is an urgent need to make operative catalysts that are well retained inside cells and ensure intracellular activities. In addition, there are many other questions that remain to be addressed. Is it possible to concentrate the catalyst within a specific organelle/environment while keeping its activity, and without generating toxicity? Would it be possible to visualize the catalyst within the cell and the organelles? Is it possible to use the confined catalyst to generate a differentiated biological effect? Could this localization provide a functional advantage?

In the present manuscript, we provide some answers to these questions by describing a designed ruthenium conjugate that is capable of accumulating in the mitochondria of living cells and promoting a localized uncaging of alloc/allyl protected exogenous substrates, reaction that operates through typical pi-allyl-mediated mechanisms (Fig. 1a,b). In addition to confirming the intracellular performance of the catalyst, this work represents the first demonstration that it is possible to generate abiotic, bioorthogonal catalytic power in subcellular compartments of living cells.

Figure 1: Aim of the present study.
Figure 1

(a) Transition metal pi-allyl chemistry. (b) Preferential accumulation of the metal catalyst in the mitochondria owing to the targeting group P. , metal complex; , mitochondria-targeting group.


Mitochondria targeting

Mitochondria are complex organelles found in almost all eukaryotic cells that play vital roles in the regulation of cellular function and survival4,26. Therefore, along the last years, there have been many efforts to engineer cell permeable vectors capable of targeting this organelle27,28,29. A particularly successful delivery platform is based on the use of triphenylphosphonium (TPP) cations, which exhibit a single positive charge resonance-stabilized over three phenyl groups and a large hydrophobic surface area. It is known that the accumulation of these type of lipophilic cationic compounds is driven by the membrane potential across the mitochondrial inner membrane30. TPP cations can be therefore taken up by the mitochondrial matrix, where they are freely soluble or adsorbed on the leaflet of the inner membrane depending on the hydrophobicity of the cargo30,31.

Even though the functional complexity of mitochondria suggests that it might be incompatible with organometallic chemistry, we were intrigued by the possibility of accumulating active transition metal complexes in this organelle using a TPP delivery vector. Following recent work on the use of discrete ruthenium catalysts to promote an orthogonal removal of alloc protecting groups13,14,15, we decided to explore the use of 2-quinolinecarboxylate (QC) ligand as platform for the introduction of the required phosphonium-targeting groups14,32. Towards this end, we prepared the complex RuL1 (Fig. 2), in which the metallic centre contains a modified QC ligand linked to a TPP group through a relatively hydrophobic alkyl chain. This new structure is a lipophilic dication that might have an intrinsic preference for accumulation in the mitochondria. The hydrophobic linker should counterbalance the Born energy of the two charges, and favour the membrane crossing processes. This complex was prepared in four steps from 4-bromoquinoline-2-carboxylic acid (1)33, via the sequence of steps shown in the Fig. 2, which involves the preparation of the ligand and its complexation to the ruthenium precursor [RuCp(CH3CN)3]PF6 (see Supplementary Methods and Supplementary Figs 1–4 for details).

Figure 2: Ruthenium complexes Ru1 and RuL1.
Figure 2

Synthesis of RuL1: (a) 1 (1.0 equiv.), allyl bromide (1.6 equiv.), KHCO3 (1.7 equiv.), DMF, 12 h, 50 °C, 75%; (b) 3-N-methyl-propanol (5.0 equiv.), DMSO, 1 h, 100 °C, 87%; (c) (3-carboxypropyl)triphenylphosphonium bromide (1.0 equiv.), EDC (2.5 equiv.), DMAP (2.0 equiv.), 12 h, room temperature, 30%; (d) [RuCp(CH3CN)3]PF6 (1.0 equiv.), DCM, 12 h, room temperature, 65%. DCM, dichloromethane; DMAP, 4-dimethylaminopyridine; DMF, N,N-dimethylformamide; EDC, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide.

For comparison purposes, we also made the parent complex Ru1, which lacks the TPP-containing appendage. Although previous studies had indicated that the catalytic activity of these ruthenium derivatives is favoured by the presence of electron donor groups in the quinoline, in the context of our research these derivatives, which demand a more elaborated synthesis, are not required14.

In vitro and cellular reactivity

To evaluate the catalytic capabilities of these complexes, we selected the transformation of the bis-allyloxycarbonyl-protected rhodamine (Rho-Alloc) into its corresponding free-amine derivative (Rho), reaction that can be monitored by fluorescence (Fig. 3a)13,14,15.

Figure 3: Uncaging experiments of Rho-alloc with Ru1 and RuL1.
Figure 3

(a) Schematic representation of the uncaging reaction of Rho-alloc. (b,c) Ru1- (b) and RuL1-(c) catalysed uncaging of Rho-alloc under biologically relevant conditions. Reaction conditions: Rho-alloc (500 μM, 1 equiv.), ruthenium complex (5 μM, 0.05 equiv.) in 120 μl solution of either HeLa cells lysates, PBS (+5 mM of glutathione, 10 equiv.) or water (+5 mM of glutathione, 10 equiv.). (d) Micrographs showing the fluorescence of the product (Rho) in cells treated with the ruthenium complexes (25 μM) for 15 min (except in case A), washed for 20 min with PBS; treated with Rho-alloc (100 μM) for 30 min and washed again for 4 min with PBS. (A) control experiment, not ruthenium complex added; (B) results with complex Ru1; (C) results with complex RuL1. (e) Fluorescent micrographies of HeLa cells after RuL1-catalysed uncaging of Rho-alloc. (D) Mitochondrial labelling with TMRE (red channel)35. (E) Fluorescence resulting from the RuL1 promoted reaction (green channel) and (F) merging of D and E. Reaction conditions: cells were incubated with RuL1 (50 μM) and TMRE (100 nM) for 30 min, followed by double washing with DMEM-FBS and incubation with Rho-alloc (100 μM) for 30 min. Scale bar, 12.5 μm. Error bars represent the standard deviation of measurements in three different samples.

Before testing the reactivity in living cells, we analysed the in vitro performance of both metal complexes using biologically relevant reaction media. The experiments were carried out using 5% of the ruthenium complex either in water, PBS (pH 7.2) or HeLa cell lysates, and a concentration of Rho-alloc of 100 μM. As it can be observed in Fig. 3a,b, the reaction rates and conversions depend on the reaction conditions. Both complexes presented activity, although RuL1 was much more active than complex Ru1 in all the media studied, even in cell lysates. In relative terms, the activity in water and PBS was always higher for both catalysts, with a substantial decrease in cell lysates. However, RuL1 led to a lower decrease than Ru1. Nevertheless, in both cases, rate and turnover were lower than those previously described for Ru1 using other substrates and reaction media, in part because of solubility problems of the probe (Supplementary Table 1)14.

Even though the reactivity was poor in the above conditions, we examined their performance in living cells using human cervical cancer cells (HeLa cells). Since our objective is the installation of artificial catalysts in a subcellular site, we carried out the experiments in an inverse way to that used in previous studies, in which the substrate was added to the cells before the catalyst13,14,15. To avoid misinterpretations arising from potential toxic effects of the metal complexes, we first analysed the cell viability. Gratifyingly, using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay34, we were glad to observe that both Ru1 and RuL1 are quite innocuous, and only promote a decrease in the viability at concentrations >100 μM (30% decrease) and after 24 h of incubation (after 2 h we did not detect any toxicity, Supplementary Fig. 5).

Considering the previously mentioned recent report suggesting that ruthenium catalysts such as Ru1 are readily washed out with PBS in cellular settings16, we performed parallel experiments to compare the catalytic performances of Ru1 and RuL1 (Fig. 3; Supplementary Fig. 6). Therefore, cultured cells were treated with either ruthenium complex Ru1 or RuL1 (25 μM) for 15 min in fresh DMEM-FBS (DMEM supplemented with 5% of fetal bovine serum), followed by washing for 20 min with PBS16. The resulting cells were then incubated with Rho-alloc (100 μM) in fresh DMEM-FBS for 30 min and washed for 4 min with PBS. In consonance with that observed by Waymouth and Wender16, the green staining inside cells treated with Ru1 was very weak (Fig. 3d, panel B). In contrast, and importantly, we observed an intense green fluorescence in cells treated with RuL1 (Fig. 3d, panel C). This suggests that the presence of the TPP appendage allows a much better intracellular retention of the complex (RuL1). It is important to note that control experiments with Ru1 revealed that if the cells are washed with DMEM-FBS instead of PBS there is clear intracellular fluorescence (Supplementary Fig. 7).

Interestingly, when the above uncaging of Rho-alloc with RuL1 (100 μM) was carried out in cells previously treated with the mitochondrial dye tetramethylrhodamine ethyl ester (TMRE, 100 μM)35, we observed that the intracellular green staining co-localizes, at least in part, with the TMRE dye (Fig. 3e, panels D–F). This was better appreciated by comparing this costaining with that obtained in cells treated with Ru1, which promoted a less intense and diffuse fluorescence signal extended across the cytoplasm (Supplementary Fig. 7). Control experiments in the absence of ruthenium complexes confirmed that there is not an observable intracellular fluorescence even after several hours of incubation with the caged fluorophore.

These results confirmed that the structure of the catalyst influences the reactivity profile, and that RuL1 generates a more intense fluorescence inside cells, mainly localized in the mitochondria surroundings. Inductively coupled plasma mass spectrometry (ICP-MS) analysis of cells incubated with equal concentrations of both complexes further confirmed that RuL1 is better retained by cells, and more concentrated in the mitochondria inside the cells, with respect to Ru1 (Supplementary Table 2).

To gain more information on the system, and to track the intracellular presence of the metal complexes, we pursued the development of derivatives equipped with fluorescent labels. Previous approaches to make fluorescent TPP cations have been based on the attachment of external fluorophores36,37. However, this strategy introduces important structural changes in the probe. We envisioned that an alternative based on the replacement of one of the phenyl rings of the phosphonium group by a pyrene derivative might allow fluorescent monitoring while keeping the required hydrophobicity/charge balance of the targeting vector. Thus, we prepared the pyrene-phosphonium complex RuL2, as well as the analogue RuL3 that lacks the phosphonium group and could therefore be used as reference (Fig. 4a; see the Supplementary Methods for synthetic details). The ultraviolet–visible spectra of RuL2 and RuL3 showed a set of bands of the QC unit centred at ca. 275 nm, whereas at lower energy there is the typical set of bands corresponding to the pyrene ring with a λmax at 345 nm. The fluorescence spectra displayed maxima at 385 and 390 nm for RuL2 and RuL3, respectively (Supplementary Fig. 8).

Figure 4: Reactivity of ruthenium complexes RuL2 and RuL3 in HeLa cells.
Figure 4

(a) Structure of the ruthenium complexes RuL2 and RuL3. (b) Subcellular localization and catalytic activity of RuL2 and (c) RuL3. (A) Mitochondrial labelling with TMRE (red), (B) emission of the metal complex (blue), (C) merging of A and B, (D) Rho fluorescence in cells preincubated with the ruthenium catalysts after addition of Rho-alloc, (E) merging of A and D, and (F) merging of B and D. Reaction conditions: cells were incubated with the catalyst (50 μM) and TMRE (100 nM) for 30 min, followed by two washings with DMEM-FBS and treatment with Rho-alloc (100 μM) for 30 min. Scale bar, 12.5 μm.

Gratifyingly, the addition of TMRE (100 nM) and RuL2 (50 μM) to HeLa cells, followed by double washing with DMEM-FBS elicited a clear intracellular blue fluorescence after 5 min of incubation (Fig. 4b, panel B), staining that presents an excellent overlay (Mander’s coefficient 90%)38 with the marker TMRE (Fig. 4b, panel C). Subsequent experiments revealed that a final catalyst concentration as low as 10 μM is even enough for the uptake and imaging. Importantly, cells treated with the conjugate RuL3, a control complex lacking the phosphonium moiety, showed a different staining pattern (Fig. 4c, panel B), as can be observed in the TMRE co-localization picture (Fig. 4c, panel C), with the fluorescence preferentially located in the perinuclear region.

Importantly, ICP experiments of cells incubated with the same concentrations of both complexes corroborated that the phosphonium-pyrene derivative RuL2 was better retained than RuL3. Moreover, ICP analysis of the ruthenium content in isolated mitochondria of the cells, revealed a much higher proportion in the cells treated with RuL2. Therefore, the presence of the pyrene moiety in RuL2 increased its cellular and mitochondrial retention with respect to the triphenylphosphonium analogue RuL1 (Supplementary Table 2), which suggests that the phosphonium-pyrene unit is an excellent mitochondrial tagging fluorescent group, and might be used for other applications39.

While the appearance and morphology of the cells suggested that both ruthenium complexes are innocuous, this was further confirmed with MTT cytotoxicity assays. As in the case of Ru1 and RuL1, both pyrene-ruthenium derivatives induced only a slight decrease of cell viability after 24 h of incubation at high concentrations (Supplementary Fig. 5).

Intracellular reactivity of the pyrene-ruthenium derivatives

The previous experiments confirmed that the complex RuL2 has excellent cell membrane permeability, can be readily taken up by the cell mitochondria, is firmly retained inside the cell (even after a 20 min PBS washing, Supplementary Fig. 6) and does not compromise cell survival. A key question now was finding out whether the mitochondria-confined complex is catalytically active. Remarkably, the addition of Rho-alloc (100 μM) to cells that had been previously treated with TMRE (100 nM) and either ruthenium complex (50 μM), and thoroughly washed with DMEM-FBS, led to intracellular green staining patterns. Interestingly, while the green emission of the reaction product (Rho) observed in cells treated with RuL2 matched almost perfectly the red fluorescence of the TMRE dye as well as the blue fluorescence coming from RuL2 (Fig. 4b, panels E and F, respectively and Fig. 5), in cells incubated with RuL3 the green fluorescence of Rho showed a much poorer correlation with the mitochondrial dye TMRE (Fig. 4c, panel E). Particularly illustrative is the comparison between the overlays obtained from RuL2 and RuL3, represented in panels E (Fig. 4b,c, respectively).

Figure 5: Co-localization studies of the ruthenium catalysts in HeLa cells.
Figure 5

(a) Co-localization coefficients (Mander’s coefficients, M1) performed on dual-colour images from fluorescent microscopy experiments represented in Fig. 4. (b) Bars representation of the Mander’s coefficients. Yellow bar: fraction of TMRE overlapping green signal of the reaction product Rho; magenta bar: fraction of TMRE overlapping blue signal of the catalyst. Error bars represent the standard deviation of measurements in three different samples.

Also importantly, similar catalytic results, that could be fully replicated, were observed when the same experiments were carried out in adenocarcinomic human alveolar basal epithelial cells (A549 cells, Supplementary Fig. 9).

Using the Mander’s method, the co-localization data were quantified and the results are displayed in Fig. 5 (ref. 40). As can be deduced from the values obtained, there is a notable difference between both catalysts. In cells incubated with RuL2, there is high co-localization of the mitochondrial marker TMRE with both the reaction product Rho and the catalyst, with values of 73% and 88%, respectively (red signal overlapping green and blue); however, the values drop to 35% in cells incubated with RuL3, which are similar to those observed for cells incubated with Ru1.

The above data are fully consistent with a pi-allyl-mediated organometallic reaction occurring in the mitochondria of living cells, reaction that generates products in a highly localized manner. Curiously, in vitro catalytic assays using cell lysates as reaction medium revealed that RuL2 (5 mol%) had a very poor performance, as we only observed a 0.2% of conversion after 4 h at 37 °C (RuL3 leads to a 12.4% conversion in the same conditions; Supplementary Table 1). Although this low activity is in great part due to solubility or aggregation problems, it comes to indicate that in vitro results do not necessarily correlate with the reactivity profile in the environment of living cells and/or specific organelles.

In consonance with the proposed mechanism of mitochondrial localization based on the membrane potential, we observed that adding a depolarizing agent-like carbonylcyanide p-triflouromethoxy-phenylhydrazone (20 nM)41 to cells pretreated with RuL2 (50 μM) promotes a diffuse blue staining no longer associated to the mitochondria. As expected, addition of the pro-fluorescent probe Rho-alloc led to an accumulation of green fluorescence throughout the cytoplasm rather than in the mitochondria (Supplementary Fig. 10).

Activation of a mitochondrial membrane-uncoupler agent

While the above experiments demonstrated that the preferential accumulation of metal complex RuL2 in mitochondria promoted a confined catalytic response, it remained to be shown whether such subcellular reactivity could provide a functional advantage. Towards this end, we paid attention to the possibility of a localized generation of 2,4-dinitrophenol (DNP), a protonophore known to decrease the mitochondrial membrane potential and switch off the ATP production (Fig. 6a)42,43. Importantly, control experiments confirmed that the allyl-caged derivative DNP-allyl failed to elicit any observable biological effect in the mitochondria, even at relatively high concentrations (500 μM). However, treatment of HeLa cells with 500 μM of the phenol-free form (DNP) produced a depolarization in the mitochondria, as can be deduced from the change in the fluorescence staining induced by the TMRE and its decrease in intensity (Fig. 6b, panel D)44. TMRE is a cell permeable, positively charged, red–orange dye that readily accumulates in active mitochondria. Depolarized or inactive mitochondria have decreased membrane potential and fail to sequester TMRE, which therefore generates a decreased intensity and a much less defined red staining (Supplementary Fig. 11).

Figure 6: Activation of DNP-allyl inside HeLa cells.
Figure 6

(a) Schematic representation of the uncaging reaction of DNP-allyl with RuL2 and RuL3. (b) Fluorescence micrographs of the mitochondrial staining with TMRE (100 nM) of: (A) cells incubated with RuL2 (50 μM), (B) cells incubated with RuL3 (50 μM), (C) cells treated with DNP-allyl (150 μM) after incubation with RuL2, (D) cells treated with DNP (500 μM) and (E) cells treated with DNP-allyl (150 μM) after incubation with RuL3. (c) Quantification of the fluorescence of the micrographs from section (b) showing the normalized decrease of the TMRE fluorescence. (d) Influence of the concentration of DNP/DNP-allyl on the mitochondrial depolarization of HeLa cells. Scale bar, 12.5 μm. Error bars represent the standard deviation of measurements in three different samples.

Using TMRE as indicator, we found that neither metal complex RuL2 nor RuL3 produced major damages in the mitochondria potential, even after 24 h (Fig. 6b, panels A and B). However, the addition of DNP-allyl (150 μM) to the cells previously treated with RuL2, produced a rapid damage in the mitochondrial membrane potential, as deduced from the considerable decrease in the TMRE fluorescence observed after 30 min (Fig. 6b, panel C). This effect must arise from the subcellular confined release of the active uncoupler DNP, because addition of the same amount of substrate to cells pretreated with RuL3, which lacks the phosphonium-targeting moiety, produced a very weak depolarization effect (Fig. 6b, panel E). This result has been reproduced not only in HeLa but also in other mammalian cells such as Vero (Supplementary Fig. 12). Therefore, the mitochondria-confined catalyst led to a much more efficient and rapid response, most probably because of an intense, confined and probably amplified release of the damaging agent (Fig. 6c).

Also important, while the generation of a reproducible damaging effect with the active drug (DNP) required the use of concentrations >500 μM, cells pretreated with RuL2 were able to generate reproducible depolarization effects employing only 150 μM of the DNP-allyl precursor (Fig. 6d), which suggests that the confined catalyst not only enables the use of an inert prodrug but also allows to decrease the dosage.

In conclusion, we have described the first non-toxic, transition metal complex that is capable to promote an abiotic organometallic catalytic transformation of designed exogenous substrates within the mitochondria of living cells. Appropriate fluorescent labelling allows tracking the intracellular localization of the metal complexes, localization that depends on the structure of the metal ligands. The use of the pyrene-phosphonium-targeting group and a hydrophobic linker allows for a preferential mitochondrial accumulation of the ruthenium complex and ensures its intracellular retention. Importantly, we have also demonstrated that the confined installation of the metal catalyst can be used to obtain functional advantages, such as a smooth and rapid ruthenium-dependent depolarization of the mitochondria. These studies, by enabling catalytic functions that are absent in nature, open new avenues and opportunities in the use of typical transition metal catalysis for the selective manipulation of living systems.



Chemical synthesis procedures, detailed protocols and characterization of all the compounds are included in the Supplementary Methods section. For NMR and high-resolution electrospray ionisation mass spectrometry (HR-ESI-MS)/MALDI-TOF analysis of the compounds in this article, see Supplementary Figs 13–25.

Synthesis of L1

Allyl 4-[(3-hydroxypropyl)(methyl)amino]quinoline-2-carboxylate was synthesized from precursor 4-bromoquinoline-2-carboxylic acid (1)33.

(3-Carboxypropyl)triphenylphosphonium bromide (46.0 mg, 0.11 mmol) was dissolved in N,N-dimethylformamide (DMF) (1 ml). 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (52.0 mg, 0.27 mmol), allyl 4-[(3-hydroxypropyl)(methyl)amino]quinoline-2-carboxylate (32.0 mg, 0.11 mmol) and 4-dimethylaminopyridine (26.0 mg, 0.22 mmol) were subsequently added to the solution. The reaction mixture was left stirring overnight and the solvent was removed under reduced pressure. The crude was purified by flash chromatography on silica gel (DCM/MeOH 9:1) yielding an off yellow liquid (23.0 mg, 30%).

Synthesis of the ruthenium complex RuL1

To a 10 mM solution of ligand L1 (1.0 equiv.) in anhydrous dichloromethane (DCM) was added 1 equiv. of [RuCp(CH3CN)3]PF6. The reaction mixture was left stirring overnight at room temperature. The reaction mixture was centrifuged, the supernatant was collected and the solvent was removed under reduced pressure yielding the complex RuL1 as a dark solid (65%).

Cell culture experiments

All cell lines were cultured in DMEM supplemented with 10% (v/v) FBS, 5 mM glutamine, penicillin (100 U ml−1) and streptomycin (100 U ml−1; all from Invitrogen). Proliferating cell cultures were maintained in a 5% CO2 humidified incubator at 37 °C. Unless otherwise specified, all incubations were performed in DMEM supplemented with 5% of FBS (DMEM-FBS) at 37 °C.

Viability assays

The toxicity of the catalysts Ru1 and RuL1RuL3 was tested by MTT assay in HeLa and A549 cell lines as follows: 15,000 cells per well were seeded in 96-well plates 1 day before treatment with different concentrations of the catalysts. After 24 h of incubation, medium containing Thiazolyl Blue Tetrazolium Bromide (Sigma) was added to a final concentration of 0.5 mg ml−1. Cells were then incubated for 4 h to allow the formation of formazan precipitates by metabolically active cells. A detergent solution of 10% SDS and 0.01 M HCl was then added and the plate was incubated overnight at room temperature to allow the solubilization of the precipitates. The quantity of formazan in each well (directly proportional to the number of viable cells) was measured by recording changes in absorbance at 570 nm in a microtitre plate reading spectrophotometer (Tecan Infinite 200 PRO).

Catalytic experiments in living cells

Uncaging of Rho-alloc. Cells growing on glass coverslips were incubated with either catalyst Ru1, RuL1, RuL2 or RuL3 (50 μM) and TMRE (100 nM) for 30 min. Cells were then washed twice with DMEM-FBS and incubated with Rho-alloc (100 μM) for 30 min. Before observation by fluorescence microscopy, the samples were washed twice with fresh DMEM-FBS. The coverslips were observed in vivo in a fluorescence microscope equipped with adequate filters. Digital pictures of the different samples were taken under identical conditions of gain and exposure.

Uncaging of DNP-allyl. Cells growing on glass coverslips were incubated with either catalyst RuL2 or RuL3 (50 μM) for 30 min. Cells were then washed twice with DMEM-FBS and incubated with the caged DNP-allyl (500 μM) for 30 min. Finally, TMRE (100 nM) was added to the incubation medium for 10 min. The coverslips were then observed in vivo in a fluorescence microscope equipped with adequate filters. Digital pictures of the different samples were taken under identical conditions of gain and exposure.

Data availability

The authors declare that the data supporting the findings of this study are available within the article and its Supplementary Information files. Other data that support the findings of this study are available from the corresponding author on request.

Additional information

How to cite this article: Tomás-Gamasa, M. et al. Transition metal catalysis in the mitochondria of living cells. Nat. Commun. 7:12538 doi: 10.1038/ncomms12538 (2016).


  1. 1.

    in How Enzymes Work: from Structure to Function 53–74(CRC Press (2015).

  2. 2.

    , , & A role for mitochondrial enzymes in inherited neoplasia and beyond. Nat. Rev. Cancer 3, 193–202 (2003).

  3. 3.

    & Mitochondrial function: OMA1 and OPA1, the grandmasters of mitochondrial health. Curr. Biol. 20, R274–R276 (2010).

  4. 4.

    , & Mitochondria: more than just a powerhouse. Curr. Biol. 16, R551–R560 (2006).

  5. 5.

    & Enzymes for chemical synthesis. Nature 409, 232–240 (2001).

  6. 6.

    , & Multistep one-pot reactions combining biocatalysts and chemical catalysts for asymmetric synthesis. ACS Catal. 3, 2856–2864 (2013).

  7. 7.

    et al. Cooperative tandem catalysis by an organometallic complex and a metalloenzyme. Angew. Chem. Int. Ed. 53, 465–469 (2014).

  8. 8.

    , , & Bioinspired catalyst design and artificial metalloenzymes. Chem. Eur. J. 17, 4680–4698 (2011).

  9. 9.

    , & Metalloenzyme design and engineering through strategic modifications of native protein scaffolds. Curr. Opin. Chem. Biol. 19, 67–75 (2014).

  10. 10.

    & Artificial metalloenzymes for enantioselective catalysis. Curr. Opin. Chem. Biol. 19, 135–143 (2014).

  11. 11.

    & Recent achievments in the design and engineering of artificial metalloenzymes. Curr. Opin. Chem. Biol. 19, 99–106 (2014).

  12. 12.

    & Latest Developments in Metalloenzyme Design and Repurposing. Eur. J. Inorg. Chem. 2015, 3406–3418 (2015).

  13. 13.

    & Ruthenium-induced allylcarbamate cleavage in living cells. Angew. Chem. Int. Ed. 45, 5645–5648 (2006).

  14. 14.

    , , & Progress towards bioorthogonal catalysis with organometallic compounds. Angew. Chem. Int. Ed. 53, 10536–10540 (2014).

  15. 15.

    , , & Metal-catalyzed uncaging of DNA-binding agents in living cells. Chem. Sci. 5, 1901–1907 (2014).

  16. 16.

    , , & Bioorthogonal catalysis: a general method to evaluate metal-catalyzed reactions in real time in living systems using a cellular luciferase reporter system. Bioconjug. Chem. 27, 376–382 (2016).

  17. 17.

    , , , & Palladium-mediated intracellular chemistry. Nat. Chem. 3, 239–243 (2011).

  18. 18.

    et al. Development and bioorthogonal activation of palladium-labile prodrugs of gemcitabine. J. Med. Chem. 57, 5395–5404 (2014).

  19. 19.

    et al. Palladium-triggered deprotection chemistry for protein activation in living cells. Nat. Chem. 6, 352–361 (2014).

  20. 20.

    , & Metal complex catalysis in living biological systems. Chem. Commun. 49, 1581–1587 (2013).

  21. 21.

    , & Palladium-mediated chemistry in living cells. Curr. Opin. Chem. Biol. 21, 128–135 (2014).

  22. 22.

    & Approaches to the design of catalytic metallodrugs. Curr. Opin. Chem. Biol. 25, 172–183 (2015).

  23. 23.

    , & Transition metal-mediated bioorthogonal protein chemistry in living cells. Chem. Soc. Rev. 43, 6511 (2014).

  24. 24.

    & Transition-metal-mediated uncaging in living human cells-an emerging alternative to photolabile protecting groups. Curr. Opin. Chem. Biol. 25, 48–54 (2015).

  25. 25.

    et al. Supramolecular regulation of bioorthogonal catalysis in cells using nanoparticle-embedded transition metal catalysts. Nat. Chem. 7, 597–603 (2015).

  26. 26.

    , , & Mitochondrial pharmacology. Trends Pharmacol. Sci. 33, 341–352 (2012).

  27. 27.

    et al. Molecular vehicles for mitochondrial chemical biology and drug delivery. ACS Chem. Biol. 9, 323–333 (2014).

  28. 28.

    & Targeting mitochondria for cancer therapy. Nat. Chem. Biol. 11, 9–15 (2015).

  29. 29.

    , , , & Targeting mitochondria. Acc. Chem. Res. 41, 87–97 (2008).

  30. 30.

    Targeting lipophilic cations to mitochondria. Biochim. Biophys. Acta 1777, 1028–1031 (2008).

  31. 31.

    , , & Delivery of bioactive molecules to mitochondria in vivo. Proc. Natl Acad. Sci. USA 100, 5407–5412 (2003).

  32. 32.

    , , & CpRuIIPF6/quinaldic acid-catalyzed chemoselective allyl ether cleavage. a simple and practical method for hydroxyl deprotection. Org. Lett. 6, 1873–1875 (2004).

  33. 33.

    , , & A facile bromination of hydroxyheteroarenes. Tetrahedron Lett. 42, 4849–4851 (2001).

  34. 34.

    & Use of MTT colorimetric assay to measure cell activation. J. Immunol. Methods 94, 57–63 (1986).

  35. 35.

    High resolution imaging of live mitochondria. Biochim. Biophys. Acta 1763, 561–575 (2006).

  36. 36.

    et al. A Highly Selective Mitochondria-Targeting Fluorescent K+ Sensor. Angew. Chem. Int. Ed. 54, 12053–12057 (2015).

  37. 37.

    et al. Fluorescent and radiolabeled triphenylphosphonium probes for imaging mitochondria. Chem. Commun. 49, 10361–10363 (2013).

  38. 38.

    & Quantifying colocalization by correlation: the pearson correlation coefficient is superior to the Mander’s overlap coefficient. Cytom. Part A 77, 733–742 (2010).

  39. 39.

    , , & MitoBlue: a nontoxic and photostable blue-emitting dye that selectively labels functional mitochondria. ACS Chem. Biol. 9, 2742–2747 (2014).

  40. 40.

    , & Measurement of co-localisation of objects in dual-colour confocal images. J. Microsc. 169, 375–382 (1993).

  41. 41.

    et al. Mitochondrial uncoupler FCCP activates proton conductance but does not block store-operated Ca(2+) current in liver cells. Arch. Biochem. Biophys. 495, 152–158 (2010).

  42. 42.

    et al. Selective uncoupling of individual mitochondria within a cell using a mitochondria-targeted photoactivated protonophore. J. Am. Chem. Soc. 134, 758–761 (2012).

  43. 43.

    et al. Assessing the mitochondrial membrane potential in cells and in vivo using targeted click chemistry and mass spectrometry. Cell Metab. 23, 379–385 (2016).

  44. 44.

    , & in Biophotonics, Part B. Methods in Enzymology 361(Elsevier Ltd (2003).

Download references


We are thankful for the support given by the Spanish grant SAF2013-41943-R, the Xunta de Galicia (GRC2013-041 and 2015-CP082), the ERDF and the European Research Council (Advanced Grant No. 340055). M.T.G. thanks the Ministerio de Economía y Competitividad for the Postdoctoral fellowship. M.M.C. thanks Ministerio de Economía y Competitividad for the Juan de la Cierva-Incorporación fellowship (IJCI-2014-19326). The authors thank R. Menaya-Vargas for excellent technical assistance and Professor P. Bermejo and Dr P. Herbello for their help with the ICP measurements, as well as Dr M.I. Sánchez for preliminary studies on the preparation of ligands.

Author information


  1. Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CIQUS), Departamento de Química Orgánica, Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain

    • María Tomás-Gamasa
    • , Miguel Martínez-Calvo
    • , José R. Couceiro
    •  & José L. Mascareñas


  1. Search for María Tomás-Gamasa in:

  2. Search for Miguel Martínez-Calvo in:

  3. Search for José R. Couceiro in:

  4. Search for José L. Mascareñas in:


M.T.G., M.M.C. and J.R.C. conducted the experiments and analysed the experimental data. M.T.G., M.M.C., J.R.C. and J.L.M. co-wrote the paper. J.L.M. guided the research.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to José L. Mascareñas.

Supplementary information

PDF files

  1. 1.

    Supplementary Information

    Supplementary Figures 1-25, Supplementary Tables 1-2, Supplementary Methods and Supplementary References

  2. 2.

    Peer review file


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Creative Commons BYThis work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit